Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Other Operating Expenses (2016 - 2024)

Historic Other Operating Expenses for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2024 value amounting to $1.6 million.

  • Ernexa Therapeutics' Other Operating Expenses changed N/A to $1.6 million in Q3 2024 from the same period last year, while for Jun 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $1.6 million for FY2024, which is 24260.87% up from last year.
  • Latest data reveals that Ernexa Therapeutics reported Other Operating Expenses of $1.6 million as of Q3 2024.
  • Ernexa Therapeutics' Other Operating Expenses' 5-year high stood at $9.6 million during Q4 2022, with a 5-year trough of -$9.6 million in Q1 2021.
  • Over the past 5 years, Ernexa Therapeutics' median Other Operating Expenses value was $1.2 million (recorded in 2020), while the average stood at $1.4 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 1606.58% in 2020, then plummeted by 62305.18% in 2021.
  • Over the past 5 years, Ernexa Therapeutics' Other Operating Expenses (Quarter) stood at $498000.0 in 2020, then tumbled by 2027.31% to -$9.6 million in 2021, then skyrocketed by 200.52% to $9.6 million in 2022, then plummeted by 95.23% to $460000.0 in 2023, then skyrocketed by 242.61% to $1.6 million in 2024.
  • Its Other Operating Expenses stands at $1.6 million for Q3 2024, versus $460000.0 for Q2 2023 and $9.6 million for Q4 2022.